Ann: Change of Director's Interest Notice-SRX.AX, page-43

I do not believe that any SRX staff have any idea as to the actual results.
Many would be very hopeful, like many of us, but that would apply to almost any company running a clinical trial. And many have failed.

All the 'evidence' we have seen, thanks to the quality of the many posters who partake, and the research items that are in the PD (albeit hard to find at times) and the reports back from conferences etc, suggest that in HCC SIRT should yield a good result. Bear in mind that history is littered with failed trials that had good data reported from small groups of pts.

My view, FWIW, is that HCC will yield a good result in at least a significant sub set, and at least match SOR, or better, as an overall result. This should give dose sales a good kick, but it may not be instant gratification.